Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Tislelizumab Plus Pemetrexed in Patients with Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

Next Previous
Trial Profile

Phase II Study of Tislelizumab Plus Pemetrexed in Patients with Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemetrexed (Primary) ; Tislelizumab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms SPECTRUM

Most Recent Events

  • 27 Mar 2025 Status changed from recruiting to active, no longer recruiting.
  • 15 Apr 2024 Planned End Date changed from 29 Feb 2024 to 28 Feb 2026.
  • 15 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top